New and experimental hepatitis C treatment: latest news

New and experimental hepatitis C treatment resources

New and experimental hepatitis C treatment features

New and experimental hepatitis C treatment news from aidsmap

More news

New and experimental hepatitis C treatment news selected from other sources

  • New hepatitis C treatments highly effective for HIV/HCV coinfected people

    A pair of interferon-free combinations -- AbbVie's 3-drug Viekira Pak regimen and Gilead Science's sofosbuvir/ledipasvir (Harvoni) -- demonstrated good safety and cured more than 90% of genotype 1 HIV/HCV coinfected people, according to studies published in the February 23 advance edition of the Journal of the American Medical Association.

    26 February 2015 | HIVandHepatitis.com
  • Health News Review analysis of Reuters' coverage of new hepatitis C drugs

    We wish that more stories would bring some skeptical thinking to their coverage of expensive new hepatitis C treatments. The emphasis on short-term effects obscures the lack of long-term data about benefits.

    13 February 2015 | Health News Review
  • UNITAID: 2015 Hepatitis C medicines technology and market landscape

    This report takes stock of a rapidly changing market, where new products have the potential to become “blockbusters” almost overnight – but also risk becoming quickly outdated due to superior products entering the market.

    13 February 2015 | UNITAID
  • FDA revokes breakthrough status for BMS hep C drug

    The big biotech tells FierceBiotech in a statement that the agency has "informed Bristol-Myers Squibb that, due to the evolving HCV treatment landscape, the agency intends to rescind the breakthrough therapy designation for certain genotype 1 hepatitis C regimens related to daclatasvir." Bristol-Myers then went on to add that the decision will not impact its timetable on an NDA for daclatasvir, which faces a unique set of challenges all its own.

    11 February 2015 | Fierce Biotech
  • Regulus Therapeutics reports top-line results from RG-101 clinical study for HCV treatment

    All HCV patients treated with a single SC administration of 4 mg/kg of RG-101 responded with mean viral load reduction of 4.8 log10 at Day 29 and 9/14 patients are below the limit of quantification at Day 57.

    11 February 2015 | Regulus Therapeutics press release
  • Promising data bodes well for all-Achillion hep C treatment

    Achillion Pharmaceuticals Inc's experimental hepatitis C drug, when used with Gilead Sciences Inc's Sovaldi, eradicated signs of the virus in six weeks, the shortest duration and highest response achieved by any two-drug treatment.

    10 February 2015 | Reuters
  • Achillion Achieves 100% SVR12 in Phase 2 Trial Evaluating 6-Week Combination Treatment With ACH-3102

    Achillion Pharmaceuticals, Inc. today announced updated interim results from the ongoing interferon-free, ribavirin-free, Phase 2 study to evaluate the efficacy, safety, and tolerability of six weeks of 50 mg of ACH-3102 and 400 mg of sofosbuvir, a marketed nucleotide polymerase inhibitor, in treatment-naïve genotype 1 HCV-infected patients.

    09 February 2015 | Achillion press release
  • Merck says hepatitis C drugs to lose breakthrough status

    Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.

    05 February 2015 | Reuters
  • AbbVie Inc stock drops after expectations for Viekira Pak fall short

    AbbVie shares fell 4.4% after market gathered from the company’s forecast that the new hepatitis C treatment may bring in just $2 billion in 2015, falling short of the high expectations.

    02 February 2015 | Bidness Etc
  • Hepatitis C drug access: Europe is the new Africa

    The remarkably high cure rates being reported with the newest hepatitis C drugs are only likely to be used by a tiny percentage of people who need them.

    30 January 2015 | HIV i-Base
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.